Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1928-1933

  Servais, Jean ^a   Lambert, Christine ^a   Plesséria, Jean Marc ^a   Fontaine, Elodie ^a   Robert, Isabelle ^a   Arendt, Vic ^a   Staub, Thérèse ^a   Hemmer, Robert ^a   Schneider, Fraņois ^a   Schmit, Jean Claude ^a  

^a NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEINASE INHIBITION; TREATMENT FAILURE; VIRUS MUTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VIRAL LOAD;

EID: 0036090610     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1928-1933.2002     Document Type: Article

References (21)

1. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
2. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
3. The median-effect principle and the combination index for quantitation of synergism and antagonism
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
6. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
7. Baseline HIV drug resistance profile predicts response to ritonavir/saquinavir protease inhibitor therapy in a community setting
8. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
9. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
10. Random-effects models for longitudinal data
11. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
12. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
13. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylaminosulfonamide inhibitors of HIV-1 aspartyl protease
14. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
15. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations
16. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 in patients failing highly active antiretroviral therapy
17. Longitudinal testing of phenotypic resistance to HIV-1 protease inhibitors in patients developing HAART failure
18. Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: The role of secondary mutations
19. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
20. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs
21. HIV genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed